Novartis Loses First Zometa Trial, Must Pay $3.2M

Law360, New York (October 23, 2009, 5:58 PM EDT) -- Novartis Pharmaceutical Corp. has lost the bellwether trial over its bone cancer drug Zometa, with a Montana jury awarding $3.2 million to a woman who accused the company of failing to adequately warn doctors of the drug's link to jaw deterioration.

After a five-day trial and eight hours of deliberation, a jury in the Missoula County District Court on Wednesday handed down its verdict in favor of Peggy Stevens, 57, who alleged she developed osteonecrosis of the jaw, or ONJ, after taking Zometa from April 2002...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.